Curanex Pharmaceuticals Inc. (CURX) Soars 10.52% on Successful IPO

On August 28, 2025, Curanex Pharmaceuticals Inc. (CURX) experienced a significant surge in its pre-market trading, rising by 10.52%. This notable increase can be attributed to the company's recent announcement of the successful closing of its initial public offering (IPO).

Curanex Pharmaceuticals Inc., a developmental stage pharmaceutical company based in Jericho, New York, has completed its IPO, raising $15 million through the sale of 3,750,000 shares of common stock at $4.00 per share. The company's shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on August 26, 2025. The underwriters for the offering include Dominari Securities LLC, Pacific Century Securities LLC, and Revere Securities LLC. The proceeds from the IPO will be used to advance the company's lead botanical drug candidate, Phyto-N, through FDA-required studies and into Phase I clinical trials. Phyto-N is a botanical extract with proven anti-inflammatory properties, targeting multiple inflammatory diseases including ulcerative colitis, atopic dermatitis, and COVID-19.

This successful IPO marks a significant milestone for Curanex, providing the necessary capital to further its research and development efforts. The company's focus on botanical drugs for inflammatory diseases positions it uniquely in the pharmaceutical market, leveraging natural compounds with a long history of human use. The favorable tolerability and multiple mechanisms of action of Phyto-N make it a promising candidate for treating a range of inflammatory conditions. With the completion of the IPO, Curanex is well-positioned to advance its clinical trials and bring innovative treatments to patients suffering from inflammatory diseases.